The text provides financial information for Boston Scientific Corporation and its subsidiaries for the quarter and six months ended June 30, 2023, comparing with the same periods in 2022. It includes consolidates financial statements, balance sheets, and statements of cash flows, outlining figures related to sales, costs, gross profit, operating income, tax expenses, net income, assets, liabilities, equity, and cash flows. Allocation of figures for expenses, investments, acquisitions, debt, stock issuances, and cash activities is also detailed. Additionally, it discusses the valuation methodology for assets and liabilities measured at fair value, categorizing inputs into Level 1, Level 2, and Level 3 based on market observability. The breakdown of fair value measurements includes assets like money market funds, time deposits, equity securities, hedging instruments, contingent consideration liability, and licensing arrangements. It elaborates on Level 3 inputs, significant unobservable inputs, changes in fair value of licensing arrangements, non-recurring measurements, and specifics on debt obligations, credit arrangements, including the revolving credit facility, financial covenants, commercial paper program, and senior notes. Furthermore, it provides a debt maturity schedule and details on borrowings and senior notes outstanding as of certain dates.
The text provides an analysis of Boston Scientific Corporation's financial condition and results of operations, emphasizing their global medical device product portfolio, net sales, operational activities, investments, acquisitions, and growth initiatives. The corporation's performance metrics, financial summaries, adjustments to GAAP measures, including non-GAAP financial measures like adjusted net income, operational net sales, organic net sales growth, and the rationale for these exclusions are highlighted. Moreover, it discussed liquidity, capital resources, operational expenses, tax rates, critical accounting policies, cybersecurity risks, legal implications, and the use of forward-looking statements, touching upon factors affecting financial results, regulatory compliance, litigation risks, innovation initiatives, international markets, and liquidity concerns. Additionally, it addresses corporate responsibility, equity aspects, recent accounting pronouncements, and risk factors associated with the business, including labor shortages, economic conditions, healthcare policy changes, cybersecurity, regulatory compliance, geopolitical risks, innovation challenges, and cost reduction strategies.
The company is involved in the development, manufacture, and global sale of medical devices, making its earnings and cash flows susceptible to market risks tied to changes in currency exchange rates and interest rates. To mitigate these risks, they utilize a risk management program that includes derivative financial instruments, with gains and losses on these instruments usually offsetting each other. Currency risks mainly stem from foreign currency denominated commitments, transactions, and subsidiary investments, managed using nonderivative and derivative instruments. Regarding interest rate risks, they typically manage U.S. dollar borrowings with derivative instruments, although they had none outstanding as of recent reports. Further details on their derivative use can be found in their financial statements.
The text discusses the evaluation of disclosure controls and procedures as of June 30, 2023, by the management team of a company, in compliance with the Securities Exchange Act of 1934. The CEO and CFO concluded that the controls and procedures were effective. Furthermore, the company is undergoing a multi-year implementation of a new global enterprise resource planning (ERP) system, which has resulted in changes to internal control over financial reporting. Future phases of this implementation are expected to impact internal controls further, requiring ongoing evaluation and potentially additional changes.
The text provides a reference to legal proceedings and directs the reader to Note H - Commitments and Contingencies in the unaudited consolidated financial statements within the Quarterly Report on Form 10-Q. This note contains further information on legal matters that pertain to the company.
Consider the risk factors discussed in the company's most recent Annual Report filed on Form 10-K, as they could significantly impact its business, financial condition, or future outcomes.
I apologize, but it seems like you have not provided any text for me to summarize. Please resend the text you would like me to summarize.
I'm sorry, but it appears that I have not yet received any parts of the text to summarize. Could you please provide me with the text so that I can summarize it for you?
I'm sorry, but I cannot provide a summary until you provide the text for me to summarize. Please go ahead and send me the text you would like me to summarize.
The text provided contains information related to corporate actions and trading plans of individuals within the company. This includes the filing of a Certificate of Elimination regarding preferred stock, as well as details of trading plans entered into by various members of the organization to comply with certain regulations. These plans outline the sale of specific numbers of common stock shares based on predetermined dates and stock price thresholds.
The text provided includes various exhibits related to financial filings, such as certificates of executives, XBRL taxonomy extensions, and signature of the report. The document pertains to Boston Scientific Corporation and includes a certificate of elimination, subsidiary issuer information, and certifications by the Chief Executive Officer and Chief Financial Officer. The report was signed by Daniel J. Brennan, the Executive Vice President, and Chief Financial Officer, on August 3, 2023.
